Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Cencora Inc.(COR)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for COR
09/28/2026: COR (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Cencora Inc. is a leading global healthcare services provider that specializes in pharmaceutical distribution and supply chain management. The company benefits from deep integration within the healthcare ecosystem and a leading position in the high-growth specialty medicine segment. While it operates with thin margins common to the wholesale industry, its essential role and scale provide stable, long-term cash flows that support consistent dividends. Investors should monitor regulatory changes in drug pricing and potential execution risks related to large-scale international acquisitions. Overall, Cencora serves as a defensive, income-oriented play, suited for investors looking for stability in the healthcare sector rather than aggressive growth.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Cencora offers steady rather than rapid, high-growth, technology-style returns. |
| Momentum investor | Mixed fit | The stock is more suited to defensive or long-term growth strategies than short-term trend chasing. |
| Value investor | Strong fit | The company trades at reasonable valuation multiples relative to its stable cash flows. |
| Dividend investor | Strong fit | Cencora is a consistent dividend payer with a sustainable payout ratio. |
| Low-risk investor | Strong fit | As a critical utility-like healthcare provider, it experiences lower volatility than more speculative sectors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Low | The stock tends to be less volatile than the broader market due to the essential nature of its business. |
| Valuation risk | Medium | Market expectations for healthcare distribution can fluctuate based on regulatory sentiment. |
| Competition risk (wholesale consolidation) | Medium | The sector is highly competitive with limited opportunity for new entry. |
| Business quality | Strong | The company operates a critical, high-barrier-to-entry infrastructure for the healthcare industry. |
| Dividend income | Low | Dividend payments are well-supported by consistent, predictable free cash flow. |
| Execution risk | Medium | Successfully integrating large-scale acquisitions is critical to future growth. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 31.99% | Avg. Invested days 60 | Today’s Advisory WEAK BUY |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/28/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 58.57B USD | Price to earnings Ratio 22.79 | 1Y Target Price 369.25 |
Price to earnings Ratio 22.79 | 1Y Target Price 369.25 | ||
Volume (30-day avg) 1.2M shares | Beta 0.57 | 52 Weeks Range 243.78 - 375.33 | Updated Date 09/27/2026 |
52 Weeks Range 243.78 - 375.33 | Updated Date 09/27/2026 | ||
Dividends yield (FY) 0.76% | Basic EPS (TTM) 13.47 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| U.S. Healthcare Solutions | Pharma distribution and pharmacy services. | The primary engine of revenue from domestic drug delivery. |
| International Healthcare Solutions | Global distribution and consulting. | Provides geographic diversification beyond the U.S. market. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 22.79 | Forward PE 15.7 | Enterprise Value 68.50B | Price to Sales(TTM) 0.18 |
Enterprise Value 68.50B | Price to Sales(TTM) 0.18 | ||
Enterprise Value to Revenue 0.21 | Enterprise Value to EBITDA 13.21 | Shares Outstanding 190.83M | Shares Floating 180.25M |
Shares Outstanding 190.83M | Shares Floating 180.25M | ||
Percent Insiders 4.3 | Percent Institutions 99.74 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Cencora Inc.
Exchange NYSE | Headquarters Conshohocken, PA, United States | ||
IPO Launch date 1995-04-04 | President, CEO & Director Dr. Robert P. Mauch Ph.D., PharmD | ||
Sector Healthcare | Industry Medical Distribution | Full time employees 47000 | Website https://www.cencora.com |
Full time employees 47000 | Website https://www.cencora.com | ||
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.